- Jasper Therapeutics ( NASDAQ: JSPR ) said that follow-up phase 1/2 data on its sickle cell disease treatment briquilimab indicated the biologic led to an increase in hemoglobin and healthy donor stem cell engraftment (donor chimerism).
- The goal of the study is to evaluate the addition of briquilimab to an existing bone marrow transplantation regimen in individuals with sickle cell disease and beta thalassemia at high risk for complications from or ineligible for myeloablative hematopoietic stem cell transplant.
- Results showed that one patient achieved 100% donor chimerism at day 30 , with the other two at day 100.
- Seeking Alpha views Jasper ( JSPR ) as a buy with high marks for momentum and revisions .
For further details see:
Jasper Therapeutics releases promising early-stage data on sickle cell disease treatment